Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.

Autor: van Hellemond IEG; Department of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., Smorenburg CH; Department of Internal Medicine, Medical Centre Alkmaar, Alkmaar, The Netherlands., Peer PGM; Biostatistics, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands., Swinkels ACP; Clinical Research Department, Netherlands Comprehensive Cancer Organization IKNL, Utrecht, The Netherlands., Seynaeve CM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van der Sangen MJC; Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands., Kroep JR; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands., de Graaf H; Department of Medical Oncology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., Honkoop AH; Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands., Erdkamp FLG; Department of Medical Oncology, Zuyderland Medical Centre, Sittard, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre, Heerlen, The Netherlands., de Roos WK; Department of Surgery, Gelderse Vallei Hospital, Ede, The Netherlands., Linn SC; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Imholz ALT; Department of Medical Oncology, Deventer Hospital, Deventer, The Netherlands., de Boer M; Department of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.; Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2020 Apr; Vol. 180 (3), pp. 675-685. Date of Electronic Publication: 2020 Mar 02.
DOI: 10.1007/s10549-020-05567-9
Abstrakt: Purpose: The phase III DATA study compared 6 and 3 years of adjuvant anastrozole following 2-3 years of tamoxifen in postmenopausal breast cancer patients. This pre-planned side-study assessed the relationship between a reduced bone mineral density (BMD) and distant recurrence-free survival (DRFS), and evaluated the effect of bisphosphonates on DRFS.
Methods: We selected all patients with a BMD measurement within 3 years after randomisation (landmark) without any DRFS events. Kaplan-Meier methods and Cox proportional hazards models were used for analyses.
Results: Of 1860 eligible patients, 1142 had a DEXA scan before the landmark. The BMD was normal in 436 (38.2%) and showed osteopenia in 565 (49.5%) and osteoporosis in 141 (12.3%) patients. After a median follow-up of 5.0 years from the landmark, neither osteopenia nor osteoporosis (compared with normal BMD) were associated with DRFS in both the 6-year [osteopenia HR 0.82 (95% CI 0.45-1.49), osteoporosis HR 1.10 (95% CI 0.26-4.67)] and the 3-year arm [osteopenia HR 0.75 (95% CI 0.40-1.42), osteoporosis HR 1.86 (95% CI 0.43-8.01)]. Moreover, bisphosphonate use did not impact DRFS.
Conclusion: No association was observed between a reduced BMD and DRFS. Neither did we observe an impact of bisphosphonates on DRFS.
Databáze: MEDLINE
Externí odkaz: